Some of yesterday's gains were sure to be short covering ... Check the volume today ... nobody is selling. Let them play their games.
AMES, Iowa, Oct. 01, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NLNK) announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has exercised an $18 million option on NewLink Genetics’ existing contract to support the scale-up of the manufacturing process relating to its investigational rVSV-ZEBOV GP (Ebola) vaccine candidate. BARDA made an initial $30 million contract award to NewLink in late 2014 and is now providing additional funding to continue development of the Ebola vaccine candidate. Merck (MRK), known as MSD outside the United States and Canada, has the license for research, development, manufacturing and commercialization of the rVSV-ZEBOV GP (Ebola) vaccine.
“This additional funding by BARDA will help NewLink and Merck accelerate large-scale production of this Ebola vaccine candidate and demonstrates government commitment to this important project," said Dr. Charles Link, CEO and Chief Scientific Officer of NewLink Genetics. “In collaboration with Merck, we will continue to work diligently to bring this vaccine candidate to patients in need as quickly as possible.”
The rVSV-ZEBOV GP (Ebola) vaccine candidate was originally developed by the Public Health Agency of Canada (PHAC) and was subsequently licensed to a subsidiary of NewLink Genetics. In late 2014, Merck licensed the vaccine from NewLink Genetics to apply Merck's vaccine expertise to help accelerate the development of this vaccine candidate. Clinical studies of the vaccine candidate are ongoing
And, it's pretty hard to dispute entering into P2 trials. They can poo poo the NIH grants all they want ... they aren't just handed out to bogus companies! The likes of SNAKO and his cronies are about to come under a microscope!!
Buyers aren't many and the few don't seem to trust the bounce. TROV is up 4% ... about the same as the rest of the bio index.
Another undervalued company is TROV ... $150M market cap with over $75M in the bank? Huge market potential!
NO ... do not buy back shares. The float is already too small and that's why there's no liquidity and we feel the pain much more in moves like this. Keep the cash and no need to dilute ... keep your eyes on the prize!!
So, the problem is that biotechs are overvalued ... ahem, 150M market cap with 75M in cash for a company that will target multi-billion dollar market(s)? Talk about the proverbial baby being thrown out with the bath water!!
I'd be surprised if we don't see some if we sit in the $4s. Sit in the $4s? Who'd a thunk it? Not trying to pick the bottom, but I was sitting on a good percentage of cash and am very content to add some in the $4.90's. Risk/reward is pretty good at these levels, even if it takes 6 more months! Think how much progress has been made and shown since we were here before?
Agreed in theory, but with no immediate catalyst what prevents this from going lower? Can't pick the bottom, but it is clear that biotech is going to get cheaper in the short term. No place to hide ...
Added to HRC's tweet about price gouging is the Dems going after Valeant Pharma for price gouging ... piling on!
Not to mention that our "public servants" in Congress can trade on insider news ahead of time. Nice gig if you can get it!